Arcus Biosciences (RCUS) Competitors $14.70 +0.42 (+2.94%) (As of 11/22/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends RCUS vs. CRNX, RNA, ADMA, ACLX, BHVN, BBIO, RARE, IMVT, OGN, and APLSShould you be buying Arcus Biosciences stock or one of its competitors? The main competitors of Arcus Biosciences include Crinetics Pharmaceuticals (CRNX), Avidity Biosciences (RNA), ADMA Biologics (ADMA), Arcellx (ACLX), Biohaven (BHVN), BridgeBio Pharma (BBIO), Ultragenyx Pharmaceutical (RARE), Immunovant (IMVT), Organon & Co. (OGN), and Apellis Pharmaceuticals (APLS). These companies are all part of the "pharmaceutical products" industry. Arcus Biosciences vs. Crinetics Pharmaceuticals Avidity Biosciences ADMA Biologics Arcellx Biohaven BridgeBio Pharma Ultragenyx Pharmaceutical Immunovant Organon & Co. Apellis Pharmaceuticals Crinetics Pharmaceuticals (NASDAQ:CRNX) and Arcus Biosciences (NYSE:RCUS) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, risk, profitability, earnings, dividends, analyst recommendations, community ranking, valuation and institutional ownership. Do insiders & institutionals believe in CRNX or RCUS? 98.5% of Crinetics Pharmaceuticals shares are owned by institutional investors. Comparatively, 92.9% of Arcus Biosciences shares are owned by institutional investors. 6.0% of Crinetics Pharmaceuticals shares are owned by insiders. Comparatively, 12.3% of Arcus Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has better valuation & earnings, CRNX or RCUS? Crinetics Pharmaceuticals has higher earnings, but lower revenue than Arcus Biosciences. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCrinetics Pharmaceuticals$1.04M5,003.75-$214.53M-$3.73-15.03Arcus Biosciences$263M5.11-$307M-$3.15-4.67 Does the MarketBeat Community believe in CRNX or RCUS? Arcus Biosciences received 40 more outperform votes than Crinetics Pharmaceuticals when rated by MarketBeat users. However, 69.06% of users gave Crinetics Pharmaceuticals an outperform vote while only 65.54% of users gave Arcus Biosciences an outperform vote. CompanyUnderperformOutperformCrinetics PharmaceuticalsOutperform Votes15469.06% Underperform Votes6930.94% Arcus BiosciencesOutperform Votes19465.54% Underperform Votes10234.46% Does the media refer more to CRNX or RCUS? In the previous week, Crinetics Pharmaceuticals had 14 more articles in the media than Arcus Biosciences. MarketBeat recorded 16 mentions for Crinetics Pharmaceuticals and 2 mentions for Arcus Biosciences. Crinetics Pharmaceuticals' average media sentiment score of 0.50 beat Arcus Biosciences' score of 0.40 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Crinetics Pharmaceuticals 6 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arcus Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk and volatility, CRNX or RCUS? Crinetics Pharmaceuticals has a beta of 0.62, meaning that its stock price is 38% less volatile than the S&P 500. Comparatively, Arcus Biosciences has a beta of 0.89, meaning that its stock price is 11% less volatile than the S&P 500. Is CRNX or RCUS more profitable? Crinetics Pharmaceuticals has a net margin of 0.00% compared to Arcus Biosciences' net margin of -102.66%. Crinetics Pharmaceuticals' return on equity of -36.12% beat Arcus Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Crinetics PharmaceuticalsN/A -36.12% -31.89% Arcus Biosciences -102.66%-45.59%-22.38% Do analysts recommend CRNX or RCUS? Crinetics Pharmaceuticals currently has a consensus price target of $70.18, suggesting a potential upside of 25.19%. Arcus Biosciences has a consensus price target of $34.00, suggesting a potential upside of 131.29%. Given Arcus Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Arcus Biosciences is more favorable than Crinetics Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Crinetics Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.91Arcus Biosciences 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00 SummaryArcus Biosciences beats Crinetics Pharmaceuticals on 10 of the 19 factors compared between the two stocks. Ad Darwin2025: Digital Asset Insights You Need to KnowCryptocurrencies are taking off again, and those in-the-know are positioning themselves to ride this wave in 2025. The question is—will you be one of them? With explosive growth on the horizon, there’s never been a better time to understand the potential gains in crypto. Our guide, Navigating the Future: Cryptos to Watch in 2025, reveals the cryptos leading this surge and the strategies to maximize your profit potential.Get your guide today! Get Arcus Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for RCUS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RCUS vs. The Competition Export to ExcelMetricArcus BiosciencesPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$1.35B$6.99B$5.38B$20.14BDividend YieldN/A8.15%5.13%3.50%P/E Ratio-4.6711.10105.1444.57Price / Sales5.11362.031,233.1517.74Price / CashN/A52.5940.4121.28Price / Book2.3810.377.094.71Net Income-$307M$153.60M$119.65M$986.85M7 Day Performance-6.37%4.60%2.25%3.76%1 Month Performance-15.25%-6.29%-2.33%4.65%1 Year Performance5.98%33.41%33.98%27.72% Arcus Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RCUSArcus Biosciences2.7564 of 5 stars$14.70+2.9%$34.00+131.3%+6.0%$1.35B$263M-4.67500CRNXCrinetics Pharmaceuticals3.5808 of 5 stars$56.06-1.7%$70.18+25.2%+82.4%$5.20B$1.04M-15.03210RNAAvidity Biosciences2.1924 of 5 stars$43.25+1.6%$63.22+46.2%+598.7%$5.16B$9.56M-15.02190Insider TradeADMAADMA Biologics3.128 of 5 stars$21.18-0.6%$21.25+0.3%+436.2%$5.01B$382.81M76.07530Insider TradeACLXArcellx2.9255 of 5 stars$90.44+3.7%$103.08+14.0%+69.4%$4.89B$110.32M-122.84130BHVNBiohaven3.8322 of 5 stars$45.59+0.9%$63.42+39.1%+50.7%$4.61B$462.51M-4.88239BBIOBridgeBio Pharma4.5819 of 5 stars$23.42+0.8%$47.57+103.1%-20.6%$4.39B$217.77M-9.72400Insider TradeNews CoverageRAREUltragenyx Pharmaceutical4.5863 of 5 stars$47.24+2.7%$87.46+85.1%+23.6%$4.36B$522.75M-7.301,276Analyst ForecastIMVTImmunovant1.4585 of 5 stars$26.87+1.2%$48.10+79.0%-17.8%$3.94BN/A-12.10120Insider TradeNews CoverageOGNOrganon & Co.4.7485 of 5 stars$15.28+2.6%$21.33+39.6%+35.9%$3.94B$6.26B3.0310,000APLSApellis Pharmaceuticals4.6222 of 5 stars$30.77+10.9%$49.94+62.3%-35.4%$3.83B$715.22M-15.16702Analyst Forecast Related Companies and Tools Related Companies Crinetics Pharmaceuticals Competitors Avidity Biosciences Competitors ADMA Biologics Competitors Arcellx Competitors Biohaven Competitors BridgeBio Pharma Competitors Ultragenyx Pharmaceutical Competitors Immunovant Competitors Organon & Co. Competitors Apellis Pharmaceuticals Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:RCUS) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcus Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcus Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RCUS Stock Alerts